ATP6V1FNB: A Potential Drug Target and Biomarker (G100130705)

Target Name: ATP6V1FNB

NCBI ID: G100130705

ATP6V1FNB

ATP6V1FNB: A Potential Drug Target and Biomarker

ATP (adenosine triphosphate) is a crucial molecule in the process of cell signaling. It is a small molecule that plays a vital role in the transfer of energy within cells. Adenosine triphosphate is generated from adenosine, a molecule that is derived from the amino acid guanine. The production of adenosine triphosphate is regulated by a variety of enzymes, including the enzyme ATP synthase.

ATP6V1FNB is a specific variant of the ATP synthase enzyme that has been identified as a potential drug target and biomarker. This molecule is unique due to its structure and function. It has a unique N-terminus that is specific for ATP synthase and is involved in the catalytic cycle. In addition, it has a unique F-terminus that is involved in the regulation of ATP synthase activity.

The research on ATP6V1FNB has led to the identification of several potential drug targets. One of the main targets is the inhibition of ATP synthase, which can lead to a decrease in the production of ATP and an increase in the levels of adenosine. This increase in adenosine levels can have a variety of effects on the body, including an increase in inflammation and an increase in the risk of certain diseases.

Another potential target of ATP6V1FNB is the regulation of ATP synthase activity. This regulation is critical for the proper function of ATP synthase and is a target for several drugs that are used to treat various diseases. By inhibiting the regulation of ATP synthase activity, these drugs can increase the levels of ATP and decrease the levels of adenosine.

In addition to its potential as a drug target, ATP6V1FNB has also been identified as a potential biomarker for several diseases. For example, ATP levels can be used as a marker for the diagnosis of certain cardiovascular diseases, such as heart failure and hypertension. In addition, ATP levels can be used as a marker for the diagnosis of certain neurological diseases, such as Parkinson's disease and Alzheimer's disease.

The discovery of ATP6V1FNB has the potential to revolutionize the field of drug development. By targeting the regulation of ATP synthase activity and the production of adenosine, researchers can develop new treatments for a variety of diseases. In addition, by identifying ATP6V1FNB as a potential biomarker, researchers can monitor the effectiveness of existing treatments and develop new ones.

In conclusion, ATP6V1FNB is a unique and promising molecule that has the potential to be a drug target and biomarker. Further research is needed to fully understand its functions and to develop new treatments based on its properties.

Protein Name: ATP6V1F Neighbor

The "ATP6V1FNB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP6V1FNB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets